Skip to content
Review Open access

Modern Cancer Diagnostics in the Era of Precision Oncology: From Liquid Biopsy and Molecular Biomarkers to Artificial Intelligence and Multi-Omics Approaches. A Scoping Review

Sep 2026 · Applied Sciences · Vol 16, pp. 9311 · 0 citations · 143 references

TL;DR

The literature indicates that cancer diagnostics is evolving from the assessment of isolated parameters towards the integration of clinical, imaging, histopathological, and molecular data, and broader clinical implementation requires further standardisation, biomarker validation, assessment of reproducibility, and confirmation of clinical utility.

Abstract

Modern oncological diagnostics increasingly integrates conventional imaging and histopathological techniques with molecular analyses, liquid biopsy, multi-omics technologies, and artificial intelligence (AI). This scoping review aimed to synthesise current knowledge on modern cancer diagnostic approaches and their role in the development of precision oncology. A literature search conducted in PubMed, Web of Science, Embase, the Cochrane Library, and Google Scholar up to 16 August 2026 identified 143 sources of evidence that met the eligibility criteria and were included in this scoping review. Unlike reviews focused on individual diagnostic technologies, this review integrates imaging diagnostics, liquid biopsy, molecular biomarkers, AI, multi-omics approaches, and patient phenotyping within a precision oncology framework. The literature indicates that cancer diagnostics is evolving from the assessment of isolated parameters towards the integration of clinical, imaging, histopathological, and molecular data. Liquid biopsy, particularly circulating tumour DNA (ctDNA) analysis, has emerged as a promising tool for disease monitoring, identifying mechanisms of treatment resistance, and detecting minimal residual disease. Genomic and multi-omics technologies provide deeper insight into tumour biology, while AI, radiomics, and digital pathology facilitate the analysis of complex diagnostic data. Nutritional status and body composition assessment also contribute valuable prognostic and predictive information. The integration of these approaches may improve risk stratification, support earlier cancer detection, enhance treatment monitoring, and facilitate personalised therapeutic decision-making. However, broader clinical implementation requires further standardisation, biomarker validation, assessment of reproducibility, and confirmation of clinical utility.

Read PDF

Similar papers

Review Open access Sep 2026

Precision Diagnostics in Prostate Cancer: Integrating Biomarkers, Imaging, Genomics, and Artificial Intelligence in Contemporary United States Practice

This review critically examines contemporary prostate cancer diagnostics within United States clinical practice, distinguishing established guideline-supported approaches from selectively used adjuncts and emerging technologies.

M. Kardjadj · 0 citations
Review Open access Sep 2026

Precision Oncology in Non-Small Cell Lung Cancer: Integrating Molecular Diagnostics, Targeted Therapies, and Resistance Mechanisms

The proposed three-tiered resistance framework provides a structured basis for understanding treatment failure, guiding molecular reassessment at progression, and informing future adaptive therapeutic strategies to improve long-term patient outcomes.

Aleksandra Litkowska, Jan Wojtas, Kaja Nadulska et al. · 0 citations
Review Open access Sep 2026

Circulating Tumor DNA in Breast Cancer: A Liquid Biopsy Revolution for Non-Invasive Genomic Profiling and Clinical Decision-Making

Continuous technological innovation, prospective multicenter validation, standardized testing protocols, and evidence-based clinical guidelines are essential to fully integrate ctDNA into routine precision breast cancer care.

E. I. Obeagu, C. Okafor · 0 citations
Review Sep 2026

Abstract A141: Precision population cancer medicine for pancreatic ductal adenocarcinoma: A framework integrating genomics, artificial intelligence, theranostics, and population health

Pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest malignancies, with a 5-year survival rate of approximately 13%. Advances in genomics, artificial intelligence (AI), liquid biopsy, and theranostics have expanded opportunities for precision oncology; however, implementation remains uneven across...

Melissa E. Heard, Madison Jones, Srinivasan Vijayakumar · 0 citations
Review Open access Sep 2026

Refining Lung Cancer Care: The Emerging Role of Liquid Biopsy in Screening, Diagnosis, and Precision Oncology

Simple Summary Lung cancer remains the leading cause of cancer-related mortality worldwide, highlighting the urgent need for more effective strategies for early detection. Timely diagnosis improves treatment options, patient survival, and quality of life while reducing healthcare costs. Although low-dose computed tomog...

Hicham Mansour, Omayma Mazouji, Ayman El Hammouti et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.